Recent Updates
Recently added Catalysts
CGON Positive Sentiment

ENDPOINTS NEWS

Thursday, December 5, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CG Oncology's bladder cancer treatment has demonstrated potential durability in a Phase 3 trial. The company recently reported positive results from its CORE-1008 Phase 2 trial, which evaluated an intravesical combination therapy for high-risk patients. Additionally, CG Oncology is set to present at upcoming investor conferences, highlighting its ongoing commitment to advancing bladder cancer treatments.
Price reaction · baseline $35.91 (2024-12-04 close) · hit pre-market · 3 other CGON headline(s) in the window, move may be shared
day 0 close · peak
-6.5%
day 1
-3.7%
day 3
-6.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • CG Oncology's treatment shows potential for durability in bladder cancer.
  • Positive results reported from the CORE-1008 Phase 2 trial.
  • Upcoming presentations at investor conferences indicate strong interest.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+139%
120-day peak, hindsight
Typical move
6.3%
average across 5 past catalysts
Cash runway
~66 mo
Minimal dilution risk
Lead asset
CG0070
Phase 2 · Non Muscle Invasive Bladder Cancer

Full Press Release Details

by admin | Dec 5, 2024 | in-the-news
CG Oncology’s bladder cancer treatment shows durability potential in Phase 3

Recent Posts

• CUA 2026 – BOND-003 Cohort C Podium
• CG Oncology to Present at Upcoming Investor Conferences in June
• SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
• CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
• AUA 2026 – CORE 008 Cohort CX Presentation

Recent Comments

Frequently Asked Questions

What is the focus of CG Oncology's recent trial?

CG Oncology's recent trial focuses on bladder cancer treatment and its durability.

What were the results of the CORE-1008 trial?

The CORE-1008 trial reported positive results for an intravesical combination therapy.

When will CG Oncology present at investor conferences?

CG Oncology is scheduled to present at upcoming investor conferences in June.

ShareAdd on Google
Tags: CGON Viatris Investor Conferences Healthcare CG Oncology bladder cancer Phase 3 CORE-1008 clinical trial
Last updated: Dec 5, 2024

Biotech snapshot

Cash runway
$1028M liquidity · $15M/mo burn
~66 mo
Minimal dilution risk
Lead asset
CG0070Phase 2
Non Muscle Invasive Bladder Cancer →

Catalyst track record

+139%
best trade around CGON's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for CGON.

See every catalyst's timing & PoA →